Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society
May 21 2019 - 2:00AM
Business Wire
POXEL S.A. (Euronext – POXEL - FR0012432516), a
biopharmaceutical company focused on the development of innovative
treatments for metabolic disorders, including type 2 diabetes and
non-alcoholic steatohepatitis (NASH), announced today that it will
be featured as a presenting company at the Jefferies 2019 Global
Healthcare Conference and the JMP Securities Life Sciences
Conference. In addition, Imeglimin will be discussed during a
symposium at the 62nd Annual Meeting of the Japanese Diabetes
Society.
- The 62nd Annual Meeting of the Japanese
Diabetes Society is being held on May 23-25, 2019 at the Sendai
International Center, Sendai, Japan. Imeglimin will be discussed in
Featured Symposium #4 on New Mode of Action Drugs to Clinical on
Thursday, May 23rd, 2019 from 2:30-5:00 PM JST.
- The Jefferies 2019 Global Healthcare
Conference is being held on June 4-7, 2019 at The Grand Hyatt
Hotel in New York City. The Company will present a corporate
overview on Wednesday, June 5th from 10:30-10:55 AM EDT and will be
available to participate in one-on-one meetings with investors. The
presentation will be webcast live. To access the webcast, please
visit the following link http://wsw.com/webcast/jeff118/poxel.pa/.
The webcast replay will remain available for 90 days following the
live presentation.
- The JMP Securities Healthcare
Conference is being held on June 19-20, 2019 at the St. Regis Hotel
in New York City. The Company will present a corporate overview on
Wednesday, June 19th from 11:30-11:55 AM EDT and will be available
to participate in one-on-one meetings with investors.
About Poxel SA
Poxel uses its development expertise in metabolism to advance a
pipeline of drug candidates focused on the treatment of metabolic
disorders, including type 2 diabetes and non-alcoholic
steatohepatitis (NASH). We have successfully completed the Phase 2
clinical program for our first-in-class lead product, Imeglimin,
which targets mitochondrial dysfunction, in the U.S., Europe and
Japan. Together with our partner Sumitomo Dainippon Pharma, we are
conducting the Phase 3 Trials of IMeglimin for
Efficacy and Safety (TIMES) program for the treatment
of type 2 diabetes in Japan. Our partner Roivant Sciences is
responsible for Imeglimin’s development and commercialization in
countries outside of Poxel’s partnership with Sumitomo Dainippon
Pharma, including the U.S. and Europe. PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is in a Phase 2a proof-of-concept program for the
treatment of NASH. PXL770 could also have the potential to treat
additional metabolic diseases. PXL065 (deuterium-stabilized
R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor,
is in Phase 1 and being developed for the treatment of NASH. Poxel
also has additional earlier-stage programs, including deuterated
drug candidates for metabolic, specialty and rare diseases. We
intend to generate further growth through strategic partnerships
and pipeline development. (Euronext:
POXEL, www.poxelpharma.com)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190520005427/en/
Poxel SAJonae R. BarnesSenior Vice President, Investor
Relations and Public
Relationsjonae.barnes@poxelpharma.com+1 617 818
2985Investor relations / Media - EU/USTrophic
CommunicationsStephanie May or Joanne Tudoricamay@trophic.eu+49 89
238 877 34 or +49 171 185 56 82Investor relations / Media -
FranceNewCapAlexia Faure/Nicolas Merigeaupoxel@newcap.eu+33 1
44 71 98 51
Poxel (EU:POXEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Poxel (EU:POXEL)
Historical Stock Chart
From Sep 2023 to Sep 2024